PDS Biotechnology Corp — Director's Dealing 2016

Jun 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-06-16

Reporting Person: Vaish Renu (V.P., Global Reg. Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-16	Common Stock	M	5000	$5.13	Acquired	5350	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-16	Stock Option (right To Purchase)	$5.13	M	5000	Disposed	2025-01-05	Common Stock (5000)	Direct

Footnotes

F1: This option, representing a right to purchase a total of 120,605 shares of Common Stock, will become exercisable on January 5, 2016, with 25% vesting on that date and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.